Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 comparison of Espad Pharmed Abobotulinum toxin A vs Dysport for skin rejuvenation
IRCT20150101020514N23Phase 3Completed
- Sponsor
- Espad Pharmed
- Start
- Oct 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of abobotulinumtoxinA in cutaneous aging (2 arms), sponsored by Espad Pharmed. Started Oct 2023; status: completed.
02
Drugs
abobotulinumtoxinA
03
Conditions
cutaneous aging
Beyond the preview
Go deeper on IRCT20150101020514N23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20150101020514N23.